| |
Samples sequenced, n
|
ST1 positive
|
ST2 positive
|
ST3 positive
|
ST4 positive
|
ST6 positive
|
Single ST n (%)
|
Two STs n (%)
|
Of double infections
|
|---|
|
ST1 + 2
|
ST1 + 3
|
ST2 + 3
|
|---|
|
By country
|
|
Azerbaijan
|
22
|
3 (14%)
|
5 (23%)
|
14 (64%)
|
0
|
0
|
22 (100%)
|
0
| | | |
|
Czechia
|
8
|
1 (13%)
|
3 (38%)
|
3 (38%)
|
1 (25%)
|
0
|
8 (100%)
|
0
| | | |
|
Jordan
|
5
|
1 (20%)
|
1 (20%)
|
4 (80%)
|
0
|
0
|
4 (80%)
|
1 (20%)
|
1
|
0
|
0
|
|
Nigeria
|
14
|
8 (57%)
|
4 (29%)
|
5 (36%)
|
0
|
1 (7%)
|
10 (71%)
|
4 (29%)
|
0
|
3
|
1
|
|
Sudan
|
24
|
14 (58%)
|
5 (21%)
|
10 (42%)
|
0
|
0
|
19 (79%)
|
5 (21%)
|
3
|
1
|
1
|
|
Tanzania
|
8
|
2 (25%)
|
2 (25%)
|
4 (50%)
|
0
|
0
|
8 (100%)
|
0
| | | |
|
By diabetes status
|
|
Type 1 diabetes
|
41
|
10 (24%)
|
11 (27%)
|
22 (54%)
|
1 (2.4%)
|
0
|
38 (93%)
|
3 (7.3%)
|
2
|
0
|
1
|
|
Healthy controls
|
40
|
19 (48%)
|
9 (23%)
|
18 (45%)
|
0
|
1 (2.5%)
|
33 (83%)
|
7 (18%)
|
2
|
4
|
1
|
|
Total (% of sequenced)
|
81
|
29/81 (35.8%)
|
20/81 (24.7%)
|
40/81 (49.4%)
|
1/81 (1.2%)
|
1/81 (1.2%)
|
71/81 (87.7%)
|
10/81 (12.3%)
|
4/81 (4.9%)
|
4/81 (4.9%)
|
2/81 (2.5%)
|
- n number of samples; % of sequenced samples
